These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30160947)

  • 41. BE-PLUS: a new base editing tool with broadened editing window and enhanced fidelity.
    Jiang W; Feng S; Huang S; Yu W; Li G; Yang G; Liu Y; Zhang Y; Zhang L; Hou Y; Chen J; Chen J; Huang X
    Cell Res; 2018 Aug; 28(8):855-861. PubMed ID: 29875396
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cell-specific CRISPR-Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins.
    Hoffmann MD; Aschenbrenner S; Grosse S; Rapti K; Domenger C; Fakhiri J; Mastel M; Börner K; Eils R; Grimm D; Niopek D
    Nucleic Acids Res; 2019 Jul; 47(13):e75. PubMed ID: 30982889
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cas9 protein variant VQR recognizes NGAC protospacer adjacent motif in rice].
    Xin GW; Hu XX; Wang KJ; Wang XC
    Yi Chuan; 2018 Dec; 40(12):1112-1119. PubMed ID: 30559100
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CRISPR-cas System as a Genome Engineering Platform: Applications in Biomedicine and Biotechnology.
    Hashemi A
    Curr Gene Ther; 2018; 18(2):115-124. PubMed ID: 29473500
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Research progress in the third-generation genomic editing technology - CRISPR/Cas9].
    Zhou Y; Zong Y; Kong X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2016 Oct; 33(5):713-6. PubMed ID: 27577230
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response.
    Haapaniemi E; Botla S; Persson J; Schmierer B; Taipale J
    Nat Med; 2018 Jul; 24(7):927-930. PubMed ID: 29892067
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CRISPR-Cpf1-mediated genome editing and gene regulation in human cells.
    Li T; Zhu L; Xiao B; Gong Z; Liao Q; Guo J
    Biotechnol Adv; 2019; 37(1):21-27. PubMed ID: 30399413
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
    Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
    Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting Specificity of the CRISPR/Cas9 System.
    Tasan I; Zhao H
    ACS Synth Biol; 2017 Sep; 6(9):1609-1613. PubMed ID: 28911233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exploration of CRISPR/Cas9-based gene editing as therapy for osteoarthritis.
    Zhao L; Huang J; Fan Y; Li J; You T; He S; Xiao G; Chen D
    Ann Rheum Dis; 2019 May; 78(5):676-682. PubMed ID: 30842121
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment.
    Xing H; Meng LH
    Acta Pharmacol Sin; 2020 May; 41(5):583-587. PubMed ID: 31792341
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Harnessing targeted DNA methylation and demethylation using dCas9.
    Pflueger C; Swain T; Lister R
    Essays Biochem; 2019 Dec; 63(6):813-825. PubMed ID: 31724704
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phosphate Lock Residues of Acidothermus cellulolyticus Cas9 Are Critical to Its Substrate Specificity.
    Hand TH; Das A; Roth MO; Smith CL; Jean-Baptiste UL; Li H
    ACS Synth Biol; 2018 Dec; 7(12):2908-2917. PubMed ID: 30458109
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System.
    Bellizzi A; Ahye N; Jalagadugula G; Wollebo HS
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):578-594. PubMed ID: 31512166
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Temperature effect on CRISPR-Cas9 mediated genome editing.
    Xiang G; Zhang X; An C; Cheng C; Wang H
    J Genet Genomics; 2017 Apr; 44(4):199-205. PubMed ID: 28412228
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-time observation of flexible domain movements in CRISPR-Cas9.
    Osuka S; Isomura K; Kajimoto S; Komori T; Nishimasu H; Shima T; Nureki O; Uemura S
    EMBO J; 2018 May; 37(10):. PubMed ID: 29650679
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Acharya S; Mishra A; Paul D; Ansari AH; Azhar M; Kumar M; Rauthan R; Sharma N; Aich M; Sinha D; Sharma S; Jain S; Ray A; Jain S; Ramalingam S; Maiti S; Chakraborty D
    Proc Natl Acad Sci U S A; 2019 Oct; 116(42):20959-20968. PubMed ID: 31570623
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeted Gene Manipulation in Plants Using the CRISPR/Cas Technology.
    Zhang D; Li Z; Li JF
    J Genet Genomics; 2016 May; 43(5):251-62. PubMed ID: 27165865
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Harnessing CRISPR/Cas 9 System for manipulation of DNA virus genome.
    Ebrahimi S; Teimoori A; Khanbabaei H; Tabasi M
    Rev Med Virol; 2019 Jan; 29(1):e2009. PubMed ID: 30260068
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reactive oxygen signaling molecule inducible regulation of CRISPR-Cas9 gene editing.
    Zhao J; Hu H; Zhou H; Zhang J; Wang L; Wang R
    Cell Biol Toxicol; 2023 Oct; 39(5):2421-2429. PubMed ID: 35644856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.